Intervju med Dr James Garner, VD Kazia Therapeutics
-
Regulatoriska pressmedddelanden 24 mars, 2023Vivesto och Elevar avser överlåta Elevars rättigheter och skyldigheter för Apealea till tredje part
-
Pressmeddelanden 20 mars, 2023Vivesto inleder klinisk utveckling av Paccal Vet inom veterinäronkologi
-
Regulatoriska pressmedddelanden 23 februari, 2023Bokslutskommuniké för räkenskapsåret 1 januari – 31 december 2022
Vivesto publicerade sin bokslutskommuniké för 2022 den 23 februari 2023 kl. 07:30.
Oasmia förvärvar globala rättigheter för utveckling och kommersialisering av Cantrixil – ett kliniskt program inom äggstockscancer
We published our Q2 results today, which show continued cost control, with a reduction in operating expenses.
#oncology #biotech
Interim report for the period January 1, 2022 – June 30, 2022 - Vivesto
SIGNIFICANT EVENTS DURING THE SECOND QUARTER In April Daniel Tesfa was appointed Chief Medical Officer. In April Vivesto signed an agreement with...
www.vivesto.com
For #investors and #media:
Today Inceptua launched Apealea® in Germany. This is great news for patients but also for Vivesto’s business as we are eligible for royalties on any sales.
#oncology #biotech
Vivesto notes the launch of Apealea® in Germany by Inceptua - Vivesto
Solna, Sweden, 15 August 2022 – Vivesto AB, an oncology-focused specialty pharmaceutical company, is pleased to note...
www.vivesto.com
This #MensHealthWeek have a look at this campaign by @menshealthforum all about how to carry out a MAN-MOT. Your car gets one regularly so why not all men? This article shows how to do your own and help early diagnosis of Prostate cancer.
Read more here:
DIY Man MOT
Your car gets one regularly but what about you? No, not a parking ticket, an MOT. Giving your body a once-over...
bit.ly